ArticleNuklearmedizin. Nuclear medicine2026
Diagnosis of hepatic alveolar echinococcosis:18F-FDG-PET activity compared to the Echinococcus multilocularis Ulm Ultrasound Classification.
Article in Nuklearmedizin. Nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alveolar echinococcosis (AE) is a rare, potentially fatal zoonosis with highly heterogeneous morphology. This study compares AE lesions in B-scan ultrasound, categorized according to the Echinococcus multilocularis Ulm Classification - Ultrasound (EMUC-US), with the maximum standardized uptake value (SUVmax) in 18F-Fluorodeoxyglucose Positron-Emission-Tomography (18F-FDG-PET/CT). 18F-FDG-PET/CT is the gold standard for evaluating disease activity, with SUVmax as the key parameter indirectly reflecting AE lesion activity.Retrospective analysis of data from the German National Echinococcosis Database. A total of 121 patients with 18F-FDG-PET/CT and B-scan ultrasound (US) between 2018-2019 were included. Based on EMUC-US, AE liver lesions were compared with the corresponding SUVmax in PET/CT. Additionally, SUV ratios (SUVTLR=tumor SUVmax/liver SUVmean) were calculated.The mean SUVmax, regardless of the EMUC-US subtype, was 6.0 ± 3.3 (range: 2.4-18.0). SUVmax comparison between subtypes shows significant differences (p<0.001). The highest SUVmax and SUVTLR were measured for the pseudocystic pattern with a mean of 9.2 ± 3.5 (range: 4.1-18.0). In contrast, the metastasis-like pattern yielded 3.7 ± 0.9 (range: 2.4-5.8) and the lowest SUVTLR. An SUVmax of 6.1 ± 3.3 (range: 2.6-16.8) was measured for the hailstorm pattern and 5.8 ± 2.2 (range: 3.6-10.4) for the hemangioma-like pattern.The results show significant differences between specific US patterns and the corresponding SUVmax. Lesions with very high or low SUV correlate with characteristic morphological patterns. Hence, in clinical practice B-scan can be a valuable bedside tool for assessing certain lesions. For evaluating inflammatory activity, 18F-FDG-PET/CT remains the method of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.